LAS VEGAS, NV / ACCESSWIRE / February 12, 2016 / Propanc Health Group Corporation (PPCH) announced this week that the Company has filed a third patent regarding the use of its lead product, PRP! The third patent covers PRP as a method to treat cancer by targeting cancer stem cell eradication, whilst sparing normal stem cells.
Cancer stem cells (CSCs) are immortal, tumor-initiating cells that have the capacity to self-renew and differentiate into other cell types. They are found in many solid tumors and, given their stem-cell like properties, are thought to be the basis for tumor initiation, development, metastasis and recurrence.
This is another large stride forward for a company that has been making a habit of pleasantly surprising investors over the past year.
Back in November, SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, issued a price target of $1.52 on Propanc Health Group Corp.. (PPCH). Currently trading at almost 2 cents a share, reaching the price target would represent a 8,500% move!
So why would See Thru Equity conclude PPCH is worth 8,500% more than its current value?
Three factors point to huge potential for Propanc:
- Positive pre-clinical study results
PPCH recently completed animal efficacy studies in mice. During the course of these studies, PPCH discovered a new target therapeutic dose range using proenzymes for treating cancer. The company filed a patent application in support of this discovery.
- Secured Capital for 12 months of Operations
Propanc recently secured $4 million from an institutional investor in order to progress their lead product, PRP, towards human trials. The total deal size is sufficient to support upcoming research and development activities in the preparation and commencement of human trials for their lead product, PRP. Also, it is expected to sufficiently cover the Company's operations over the next 12 months.
- Cell Culture Studies Prompt Patent Application
PPCH recently made some discoveries while undertaking cell culture studies on the mechanism of action of proenzymes with its research partners in Spain - the Universities of Granada and Jaén and expect to file a patent application on the subject matter soon.
See Thru Equity issued this price target before this week's massive news. It's fair to assume that this latest development may raise the potential ceiling on this biotech darling. Investors should monitor PPCH extremely closely.
A few other biotechs have investors seeing green:
Another speculative biotech play with huge potential, is Idera Pharmaceuticals (NASDAQ: IDRA). In December, Idera announced positive results from a phase 1/2 clinical trial for experimental drug IMO-8400 targeting treatment of Waldenstrom's macroglobulinemia (WM), a rare type of non-Hodgkin lymphoma. That news sent Idera's stock soaring, but share prices have given up all of those gains in the subsequent weeks.
Idera could benefit from several possible catalysts in 2016. More results from the clinical trial of IMO-8400 focusing on WM are expected later in the year. Another clinical study of the drug as a potential treatment of diffuse large B cell lymphoma is scheduled to finish in June. Idera also anticipates announcing results in 2016 from a phase 1/2 trial of TLR agonist IMO-2125 in combination with ipilimumab.
Conatus Pharmaceuticals (NASDAQ: CNAT) announced this week that the U.S. Food and Drug Administration granted a Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis caused by nonalcoholic steatohepatitis (NASH).
The Fast Track designation provides greater access to the FDA to facilitate development and expedite reviews of drugs that have demonstrated the potential to treat serious and/or life-threatening conditions. Investors are flocking to CNAT on the heels of this news.
Hemispherx Biopharma, Inc.(NYSE MKT: HEB) recently, a Voluntary Pay for Stock Plan. Senior Management believes that this Plan creates significant shareholder value as the participants will voluntarily use up to 20% of their salaries to purchase stock from the Company, creating long term incentives for them to reach corporate goals. In addition, the CEO/Chairman and President/CFO, will both voluntarily reduce their salaries further to a cumulative reduction of 50%. Investors have reacted favorably to the news as HEB remains a stock to watch.
These biotechs are providing plenty of potential for investors in the new year. Do your due diligence and take advantage of these opportunities.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.commay from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC. has been compensated $39,000 by Propanc Health Group, Corp. for this news article and for previous as well as future news articles.
Contact:
SOURCE: ACR Communication, LLC
